|dc.description.abstract||ENGLISH ABSTRACT: Radiotherapy in the Management of Carcinoma of the Vulva in Human Immune-Deficiency Virus
(HIV) Positive and Negative Patients: An Institutional Experience.
Department of Medical Imaging and Clinical Oncology, Division of Radiation and Clinical Oncology,
Tygerberg Academic Hospital and the University of Stellenbosch
Background: Radiotherapy and chemotherapy are integral parts of the effective and optimal management
of patients with vulva cancer, especially when initiated early in the course of this disease. Often, surgical
resection alone cannot effect total removal of the tumour or may not be feasible.
Human Immune-Deficiency Virus (HIV) infection has been an epidemic in sub-Saharan Africa. Highly
Active Antiretroviral Therapy (HAART) is available in public health facilities in the region to arrest and
control HIV infection, delaying the progression to AIDS and death. Infection with HIV has now been
transformed into a manageable, chronic disease and this has allowed patients to live longer, healthier and
more productive lives.
Human Immune-Deficiency Virus (HIV) infection may further complicate the management of vulva
cancer disease as patients are immunocompromised and may have difficulty in completing treatments
This study aims to identify and assess the outcomes, tolerances, toxicities and factors influencing
treatment completion in both HIV positive and negative patients with vulva cancer treated at Tygerberg
Study Design and Methods: This is a retrospective, observational, cross-sectional review of the factors
influencing the completion of radical radiotherapy in the treatment of locally advanced cancer of
the vulva. Patients are classified as either HIV positive or HIV negative. The period of the study was
between 1st. January 2007 and 31st December 2012 and it was conducted at the Division of Radiation
Oncology, Tygerberg Academic Hospital, Cape Town, South Africa. All the HIV positive patients were already on antiretroviral therapy at the outset. The disease and
treatment characteristics are described as well as toxicities of treatment of patients undergoing
radiotherapy and chemo-radiation.
Treatment completion for the two groups is evaluated. The toxicities that led to treatment interruptions for
these groups are also listed.
Results: Of the 68 patients screened, 25 met inclusion criteria; of these patients, seven (28%) were HIV
positive while the other 18 (72%) were negative. Vulva cancer patients infected with HIV presented at a
younger age and with more locally advanced tumours compared to HIV negative patients. There is no
statistically significant difference between the two groups in treatment completion rates and tumour
This retrospective study concludes that HIV positive patients with vulva cancer presented with a more
locally advanced disease and at a younger age when compared to HIV negative patients. There was no
statistically significant difference in overall therapeutic outcomes although cutaneous toxicities were
more pronounced in the HIV positive subset. Chemo-radiotherapy sequentially or concurrently can be
regarded as a standard of care in both HIV positive and negative patients provided that the HIV patients
are on antiretroviral therapy.||en_ZA